These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12696390)

  • 41. Smoke-free workplaces would hit tobacco profits.
    Eaton L
    BMJ; 2005 Feb; 330(7487):325. PubMed ID: 15705676
    [No Abstract]   [Full Text] [Related]  

  • 42. [Money or life?].
    Wildner M
    Gesundheitswesen; 2008 Jun; 70(6):327-8. PubMed ID: 18661454
    [No Abstract]   [Full Text] [Related]  

  • 43. An economic analysis of tobacco elimination policies in Turkey.
    Arslanhan S; Caner A; Helvacioglu K; Saglam I; Teksoz T
    Health Policy; 2012 Jul; 106(2):149-60. PubMed ID: 22473246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reductions in tobacco smoke pollution and increases in support for smoke-free public places following the implementation of comprehensive smoke-free workplace legislation in the Republic of Ireland: findings from the ITC Ireland/UK Survey.
    Fong GT; Hyland A; Borland R; Hammond D; Hastings G; McNeill A; Anderson S; Cummings KM; Allwright S; Mulcahy M; Howell F; Clancy L; Thompson ME; Connolly G; Driezen P
    Tob Control; 2006 Jun; 15 Suppl 3(Suppl 3):iii51-8. PubMed ID: 16754947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Legislation on smoking at workplace and in public places in Europe].
    Sasco AJ; Mélihan-Cheinin P; d'Harcourt D
    Rev Esp Salud Publica; 2003; 77(1):37-73. PubMed ID: 12696388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The strategy for supporting anti-tobacco activities in Poland, "Project on tobacco-free workplace"].
    Korzeniowska E; Puchalski K
    Med Pr; 2002; 53(6):485-8. PubMed ID: 12701540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reducing the burden of smoking world-wide: effectiveness of interventions and their coverage.
    Jha P; Chaloupka FJ; Corrao M; Jacob B
    Drug Alcohol Rev; 2006 Nov; 25(6):597-609. PubMed ID: 17132576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current tobacco control policy trends in the United States.
    Stoner WI; Foley BX
    Clin Occup Environ Med; 2006; 5(1):85-99, ix. PubMed ID: 16446256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tobacco use: the impact of prices.
    Leverett M; Ashe M; Gerard S; Jenson J; Woollery T
    J Law Med Ethics; 2002; 30(3 Suppl):88-95. PubMed ID: 12508509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What cigarettes do to American business.
    Bus Health; 1997; 15(8 Suppl A):6-31. PubMed ID: 10173766
    [No Abstract]   [Full Text] [Related]  

  • 51. Relationship of organizational characteristics of Canadian workplaces to anti-smoking initiatives.
    Frankish CJ; Johnson JL; Ratner PA; Lovato CY
    Prev Med; 1997; 26(2):248-56. PubMed ID: 9085395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.
    Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L;
    Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Public opinion on smoke-free policies among Egyptians.
    Radwan GN; Emam AH; Maher KM; Mehrez M; El-Sayed N; El-Nahas GM
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1412-7. PubMed ID: 22863614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
    Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
    Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tobacco in the workplace.
    Osinubi OY; Slade J
    Occup Med; 2002; 17(1):137-58, vi. PubMed ID: 11726342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of pharmacy data to evaluate smoking regulations' impact on sales of nicotine replacement therapies in New York City.
    Metzger KB; Mostashari F; Kerker BD
    Am J Public Health; 2005 Jun; 95(6):1050-5. PubMed ID: 15914832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A "smoke-free" hospital in Israel--a possible mission.
    Donchin M; Baras M
    Prev Med; 2004 Sep; 39(3):589-95. PubMed ID: 15313099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Public health or social impacts? A qualitative analysis of attitudes toward the smoke-free legislation in Scotland.
    Heim D; Ross A; Eadie D; MacAskill S; Davies JB; Hastings G; Haw S
    Nicotine Tob Res; 2009 Dec; 11(12):1424-30. PubMed ID: 19875764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical and pharmacological direct costs of a 9-week smoking cessation programme.
    Wasserfallen JB; Digon P; Cornuz J
    Eur J Prev Cardiol; 2012 Jun; 19(3):565-70. PubMed ID: 21450562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A report on the New South Wales Tobacco Action Plan 2001-2004.
    Mitchell JA; Hailstone S
    N S W Public Health Bull; 2004; 15(5-6):95-8. PubMed ID: 15543241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.